SBI Securities
RAPP icon

SBI Securities’s Rapport Therapeutics RAPP Stock Holding History

SBI Securities’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21K Sell
53
-10
-16% -$368 ﹤0.01% 2524
2026
Q1 		$1.97K Hold
63
– – ﹤0.01% 2423
2025
Q4 		$1.91K Buy
63
+10
+19% +$277 ﹤0.01% 2400
2025
Q3 		$1.57K Buy
53
+30
+130% +$535 ﹤0.01% 2518
2025
Q2 		$262 Buy
+23
New +$244 ﹤0.01% 3230

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cormorant Asset Management
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Sofinnova Investments
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SBI Securities's RAPP Position: Q2 2026 in Review

SBI Securities reduced its Rapport Therapeutics (RAPP) stake by 16% in Q2 2026, selling an estimated $368 and leaving 53 shares worth $2.21K. The position accounts for ﹤0.01% of the portfolio, ranked #2524.

SBI Securities first reported a position in RAPP in Q2 2025 and has held it in 5 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • SBI Securities held 53 shares of Rapport Therapeutics worth $2.21K as of Q2 2026.
  • SBI Securities sold 10 Rapport Therapeutics shares in Q2 2026, an estimated $368.
  • Rapport Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2524 holding.
  • SBI Securities first reported a position in Rapport Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.